Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Fertility and PRRT: A Guide for Young NET Patients
If you are young and your oncologist has recommended Lu-177 DOTATATE for your neuroendocrine tumor, fertility deserves its own conversation before your first cycle. Here is what the FDA prescribing information and clinical evidence say about protecting your reproductive health during PRRT.
Managing Fatigue During and After Lu-177 PSMA Therapy: What Causes It, What to Expect, and How to Recover
Fatigue is the most common side effect during Lu-177 PSMA therapy for advanced prostate cancer. This guide explains what causes it, how it changes across each six-week cycle, and what the evidence says about managing it and recovering.
Lu-177 PSMA After Docetaxel: mCRPC Eligibility Guide
If docetaxel chemotherapy has stopped controlling your metastatic castration-resistant prostate cancer, Lu-177 PSMA therapy may be the next evidence-based option available to you. Here is what the clinical data says about eligibility, sequencing, and access.
How Lu-177 DOTATATE Works: Targeting Somatostatin Receptors
Lu-177 DOTATATE (PRRT) works by binding to somatostatin receptor 2 on GEP-NET tumor cells and delivering targeted beta radiation from inside the cell. Here is what the science shows about how it works, who qualifies, and what the NETTER-1 trial found.
Lu-177 PSMA Therapy Cost in India vs the US: Real Numbers
Lutetium PSMA therapy can cost over USD 120,000 for a full course in the United States. In India the same treatment may be available for 60 to 85 percent less. Here are the real numbers, why the gap exists, and what your options are.
Metastatic Prostate Cancer Spread to Liver or Lungs - Can You Get Lu-177 PSMA for Visceral Metastases, and What Changes in Your Treatment Plan?
When prostate cancer spreads to the liver or lungs, Lu-177 PSMA therapy may still be an option - if those lesions express PSMA. Learn what eligibility requires, what the clinical evidence shows, and how visceral spread changes your treatment plan.
What Baseline Factors Predict Whether You'll Respond Well to Lu-177 PSMA Therapy - Understanding Your Prognosis Before Treatment Starts
Not every man with advanced prostate cancer responds to Lu-177 PSMA therapy in the same way. Learn which baseline factors - from your scan results to your blood tests - help predict whether this treatment may work well for you.
As a Caregiver or Partner, How Do You Help Decide Whether Lu-177 PSMA Therapy Is Right for Your Husband - A Decision-Making Guide
If your husband has advanced prostate cancer and you are trying to understand whether Lu-177 PSMA therapy might help, this guide walks you through the eligibility process, the evidence, and how to take an active role in the decision without adding more confusion to an already difficult situation.
How to Protect Your Kidney Function During Lu-177 PSMA Therapy for Bone Metastases — What the Evidence Says About Monitoring and Support
If you are considering Lu-177 PSMA therapy for bone-metastatic prostate cancer, you may be worried about what it does to your kidneys. This guide explains what the evidence shows about kidney safety, how monitoring works cycle by cycle, and what steps may support renal health during treatment.
What Blood Tests and Scans Do You Need Before Lu-177 PSMA Treatment — A Patient Guide to Pre-Therapy Eligibility Screening for Metastatic Prostate Cancer
Before starting Lu-177 PSMA therapy for metastatic prostate cancer, your care team needs a specific set of blood tests and imaging scans to confirm you are both eligible and safe to treat. This guide explains each test — what it measures, what numbers are needed, and why passing both the imaging and laboratory gates matters before treatment can begin.
Your PSMA PET Scan Came Back Negative or Very Faint — What to Do When Lu-177 PSMA Isn't an Option
A negative or very faint PSMA PET scan means you may not qualify for Lu-177 PSMA therapy right now — but it does not close every door. This article explains what the result means, why it happens, and what evidence-based treatment paths may still be open to you.
How to Read Your PSMA PET Scan: A Patient Guide to Understanding Your Imaging and Your Lu-177 Eligibility
Your PSMA PET scan report is full of terms most patients have never encountered. This guide breaks down exactly what those terms mean — and how your scan result connects directly to whether you may qualify for Lu-177 PSMA therapy.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.